504 related articles for article (PubMed ID: 29429151)
1. The Role of Hippo Pathway in Cancer Stem Cell Biology.
Park JH; Shin JE; Park HW
Mol Cells; 2018 Feb; 41(2):83-92. PubMed ID: 29429151
[TBL] [Abstract][Full Text] [Related]
2. Regulation of the Hippo pathway in cancer biology.
Moon S; Yeon Park S; Woo Park H
Cell Mol Life Sci; 2018 Jul; 75(13):2303-2319. PubMed ID: 29602952
[TBL] [Abstract][Full Text] [Related]
3. The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer.
Li Z; Wang Y; Zhu Y; Yuan C; Wang D; Zhang W; Qi B; Qiu J; Song X; Ye J; Wu H; Jiang H; Liu L; Zhang Y; Song LN; Yang J; Cheng J
Mol Oncol; 2015 Jun; 9(6):1091-105. PubMed ID: 25704916
[TBL] [Abstract][Full Text] [Related]
4. WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy.
Qi S; Zhu Y; Liu X; Li P; Wang Y; Zeng Y; Yu A; Wang Y; Sha Z; Zhong Z; Zhu R; Yuan H; Ye D; Huang S; Ling C; Xu Y; Zhou D; Zhang L; Yu FX
Mol Cell; 2022 May; 82(10):1850-1864.e7. PubMed ID: 35429439
[TBL] [Abstract][Full Text] [Related]
5. PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway.
Fujimoto D; Ueda Y; Hirono Y; Goi T; Yamaguchi A
Oncotarget; 2015 Oct; 6(33):34788-99. PubMed ID: 26431277
[TBL] [Abstract][Full Text] [Related]
6. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway.
Meng Z; Moroishi T; Mottier-Pavie V; Plouffe SW; Hansen CG; Hong AW; Park HW; Mo JS; Lu W; Lu S; Flores F; Yu FX; Halder G; Guan KL
Nat Commun; 2015 Oct; 6():8357. PubMed ID: 26437443
[TBL] [Abstract][Full Text] [Related]
7. Ski regulates Hippo and TAZ signaling to suppress breast cancer progression.
Rashidian J; Le Scolan E; Ji X; Zhu Q; Mulvihill MM; Nomura D; Luo K
Sci Signal; 2015 Feb; 8(363):ra14. PubMed ID: 25670202
[TBL] [Abstract][Full Text] [Related]
8. Roles of RUNX in Hippo Pathway Signaling.
Passaniti A; Brusgard JL; Qiao Y; Sudol M; Finch-Edmondson M
Adv Exp Med Biol; 2017; 962():435-448. PubMed ID: 28299672
[TBL] [Abstract][Full Text] [Related]
9. Expression of hippo pathway in colorectal cancer.
Liang K; Zhou G; Zhang Q; Li J; Zhang C
Saudi J Gastroenterol; 2014; 20(3):188-94. PubMed ID: 24976283
[TBL] [Abstract][Full Text] [Related]
10. Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers.
Gu Y; Wang Y; Sha Z; He C; Zhu Y; Li J; Yu A; Zhong Z; Wang X; Sun Y; Lan F; Yu FX
Cell Rep; 2022 Aug; 40(9):111296. PubMed ID: 36044856
[TBL] [Abstract][Full Text] [Related]
11. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
[TBL] [Abstract][Full Text] [Related]
12. The Hippo Pathway: Biology and Pathophysiology.
Ma S; Meng Z; Chen R; Guan KL
Annu Rev Biochem; 2019 Jun; 88():577-604. PubMed ID: 30566373
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
14. The regulation and function of YAP transcription co-activator.
Zhu C; Li L; Zhao B
Acta Biochim Biophys Sin (Shanghai); 2015 Jan; 47(1):16-28. PubMed ID: 25487920
[TBL] [Abstract][Full Text] [Related]
15. Lipid kinase PIP5Kα contributes to Hippo pathway activation via interaction with Merlin and by mediating plasma membrane targeting of LATS1.
Le TPH; Nguyen NTT; Le DDT; Anwar MA; Lee SY
Cell Commun Signal; 2023 Jun; 21(1):149. PubMed ID: 37337213
[TBL] [Abstract][Full Text] [Related]
16. Hippo pathway in mammary gland development and breast cancer.
Shi P; Feng J; Chen C
Acta Biochim Biophys Sin (Shanghai); 2015 Jan; 47(1):53-9. PubMed ID: 25467757
[TBL] [Abstract][Full Text] [Related]
17. Hippo Signaling Pathway in Gliomas.
Masliantsev K; Karayan-Tapon L; Guichet PO
Cells; 2021 Jan; 10(1):. PubMed ID: 33477668
[TBL] [Abstract][Full Text] [Related]
18. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
[TBL] [Abstract][Full Text] [Related]
19. The deadly cross-talk between Hippo pathway and epithelial-mesenchymal transition (EMT) in cancer.
Akrida I; Bravou V; Papadaki H
Mol Biol Rep; 2022 Oct; 49(10):10065-10076. PubMed ID: 35604626
[TBL] [Abstract][Full Text] [Related]
20. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
Jang JW; Kim MK; Bae SC
Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
